Followers | 149 |
Posts | 17898 |
Boards Moderated | 0 |
Alias Born | 04/12/2012 |
Tuesday, March 28, 2017 2:47:50 PM
Athena Board Member
CEO, Founder at DARÉ Bioscience
Sabrina Martucci Johnson is a life sciences executive with a record of achievement in capital formation, business development and commercial leadership. Highlights from her 20+ year career include: $170M equity raises, a business development deal sheet comprised of in-license, out-license, and M&A, and executing numerous successful product launches. Sabrina’s unique background spans finance, global marketing, product development and bench research.
Sabrina is committed to advancing innovations in women’s health. In 2015 she founded DARÉ Bioscience to bring novel technologies that clearly address unmet needs to the clinic so that the latest concepts in women’s health make it to market.
Sabrina also currently serves as CFO/COO of Calibr – California Institute for Biomedical Research. Calibr is an independent, not for profit organization focused on translational research. Calibr’s mission is to discover and develop innovative therapies that address unmet medical needs through partnerships with experts in academia and industry.
Prior to founding DARÉ Bioscience, in her role as President of WomanCare Global Trading, which includes WomanCare Global’s US and Global commercial companies, Sabrina was responsible for new innovation, including accessing capital and expanding the global product portfolio in women’s healthcare. WomanCare Global is a specialty pharmaceutical company in the female reproductive healthcare space with commercial product distribution in over 100 countries.
Sabrina was formerly a key member of the executive management team at Cypress Bioscience, Inc. (NASDAQ:CYPB) where she most recently served as Chief Operating Officer and Chief Financial Officer. At Cypress she executed mergers, acquisitions, divestitures, strategic partnerships, and capital raises (~$170 million), managed investor relations and commercial organizations, launched 4 products, and oversaw competitive analysis and market opportunity assessment and planning. She was part of the transaction team that negotiated a 160% premium for Cypress shareholders with a deal valued over $250 million.
Sabrina has also provided executive advisory services to clients in the biotechnology, pharmaceutical and diagnostic industries. Clients included: HUYA Bioscience International (COO, CFO); Kyalin Biosciences, Inc. (Secretary, Treasurer – sale of company); WomanCare Global (CFO); Ridge Diagnostics (business development); 1798 Consultants (marketing strategy); Ocera Therapeutics, Inc. (international brand strategy); Algynomics, Inc. (business plan, funding strategy).
She previously held marketing and sales positions with Advanced Tissue Sciences, where she was responsible for global product positioning for 2 product launches, and spent a year in technical sales at Clonetics Corporation. She began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on their recombinant factor VIII program.
In the community Sabrina is dedicated to organizations that serve women and girls and promote education. She serves on the YWCA of San Diego County Board of Directors as incoming President, Athena Board of Directors, Tulane University School of Science & Engineering Board of Advisors, University California San Diego Librarian’s Advisory Board, and Project Concern International Audit Committee. She has been an Entrepreneur-in-Residence for the CONNECT Springboard program for entrepreneurs, and has been a Career Horizons Mentor for Just in Time for Foster Youth. Sabrina is the incoming Co-President of Women Give San Diego, which funds non-profit organizations serving women & girls in San Diego.
Sabrina has an MIM from the American Graduate School of International Management (Thunderbird) with honors, a MSc. in Biochemical Engineering from the University of London, University College London, and a BSc. in Biomedical Engineering from Tulane University, where she graduated magna cum laude.
http://www.athenasd.org/sabrina-johnson
Recent DARE News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 08:12:44 PM
- Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise • IH Market News • 03/28/2024 11:42:00 AM
- Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024 • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 09:18:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:15:12 PM
- Daré Bioscience Announces Executive Team and Board of Directors Changes • GlobeNewswire Inc. • 01/26/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:30:23 PM
- Daré Bioscience Announces Grant to Support Biotherapeutic Product Development • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:38 PM
- Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 01:05:34 PM
- Daré Bioscience Secures $12 million in Royalty-backed Investment Structure • GlobeNewswire Inc. • 12/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 01:05:38 PM
- Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study • GlobeNewswire Inc. • 12/20/2023 01:00:00 PM
- Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study • GlobeNewswire Inc. • 12/13/2023 01:00:00 PM
- Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM